Company news
Revolution Medicines, Inc. (NASDAQ:RVMD) news
Every Revolution Medicines, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
September 14, 2026
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
September 2, 2026
U.S. FDA Approves Revolution Medicines' RASONQUE (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
August 27, 2026
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
August 26, 2026
Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration
August 11, 2026
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
August 5, 2026
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
July 29, 2026
Revolution Medicines New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
July 23, 2026
Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
July 22, 2026
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
July 7, 2026
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
July 2, 2026
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
June 24, 2026
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
June 23, 2026
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
June 22, 2026
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
May 31, 2026
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
May 21, 2026
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
May 6, 2026
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
May 6, 2026
Revolution Medicines : Statement on FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer
May 1, 2026
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
April 29, 2026
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
April 21, 2026
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
April 21, 2026
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
April 19, 2026
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 17, 2026
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
April 15, 2026
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
April 13, 2026
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
April 2, 2026
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
March 17, 2026
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
February 25, 2026
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
February 24, 2026
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
February 23, 2026
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
February 18, 2026
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
February 4, 2026
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
January 29, 2026
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
January 8, 2026
Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy
December 18, 2025
Delphia Therapeutics Appoints Leading Cancer Expert Steve Kelsey, M.D., to Board of Directors
December 9, 2025
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
November 5, 2025
Revolution Medicines to Participate in November 2025 Investor Conferences
November 4, 2025
Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025
October 29, 2025
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
October 27, 2025
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
October 22, 2025
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program
October 16, 2025
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
September 29, 2025
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
September 10, 2025
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
August 6, 2025
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
July 30, 2025
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
July 24, 2025
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
July 23, 2025